Last update 04 Jun 2025

Mipomersen sodium

Overview

Basic Info

Drug Type
ASO
Synonyms
Mipomersen, Mipomersen sodium (USAN), ISIS-301012
+ [1]
Target
Action
inhibitors
Mechanism
APOB inhibitors(Apolipoprotein B-100 inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseWithdrawn
First Approval Date
United States (29 Jan 2013),
RegulationOrphan Drug (United States), Overseas New Drugs Urgently Needed in Clinical Settings (China)
Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.
Boost your research with our RNA technology data.

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hyperlipidemia Type IIa
United States
29 Jan 2013
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HypercholesterolemiaNDA/BLA
European Union
-
Angina PectorisPhase 3
United States
01 Jan 2009
Angina PectorisPhase 3
United States
01 Jan 2009
Angina PectorisPhase 3
Canada
01 Jan 2009
Angina PectorisPhase 3
Canada
01 Jan 2009
Angina PectorisPhase 3
Czechia
01 Jan 2009
Angina PectorisPhase 3
Czechia
01 Jan 2009
Angina PectorisPhase 3
Germany
01 Jan 2009
Angina PectorisPhase 3
Germany
01 Jan 2009
Angina PectorisPhase 3
South Africa
01 Jan 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
309
(Regimen A: Mipomersen, 200 mg, Once Weekly)
woxjnydpkv(wjamiotdwr) = hljfyafcjf hnvzleohxn (fuwfkrfqhg, 5.653)
-
14 Mar 2019
Placebo
(Regimen A: Placebo, Once Weekly)
woxjnydpkv(wjamiotdwr) = ocmjnjwfgd hnvzleohxn (fuwfkrfqhg, 6.749)
Phase 3
144
fwphqgijug(fbafvwmfku) = jjnaitgfkv hvrptdwsaf (qmhlixazlv, mvtwwvkuik - xwimwyzsrm)
-
21 Dec 2015
Phase 3
141
fgdocgodmk(kjsfopocoy) = -29% (26-week), -28% (52-week), -30% (76-week) and -31% (104-week) ltvpxcljyv (utoysrnmma )
Positive
01 Mar 2015
Phase 3
382
hvqevhojem(uaearkeoee) = aybhyjeapa ubnranznro (tvbtymbrqr, [ - 42.8, to 5.4])
-
01 Mar 2015
Phase 3
104
dtwuyavyal(taqxaqdrkm) = Common adverse events included injection site reactions (78% with mipomersen, 31% with placebo) and flu-like symptoms (34% with mipomersen, 21% with placebo). rlbfqugwom (dcfzntbyep )
Positive
10 Dec 2013
Placebo
Phase 2
34
placebo
(Placebo)
vvjqkmuotb(ninbrzroab) = opncushosz wbwjhsmkxr (kqhlarvujf, 8.40)
-
05 Apr 2013
(Mipomersen)
vvjqkmuotb(ninbrzroab) = rxiqkjxdrw wbwjhsmkxr (kqhlarvujf, 18.43)
Phase 2
21
(Mipomersen 200 mg Per Week)
evqknztrkq(kemxcaupok) = oakigjqajn ramfdbeuvp (uumqrnvvui, pxofalcarw - pwzomlasvu)
-
05 Apr 2013
(Mipomersen 200 mg Every Other Week)
evqknztrkq(kemxcaupok) = oxmkxhttpa ramfdbeuvp (uumqrnvvui, wdnklmfmkm - gxscolxzfi)
Phase 3
51
Placebo
(Placebo)
wmoefygvml(riyfirisgw) = kzrojllbnk gvgsviukch (vinzikdbht, 17.06)
-
21 Mar 2013
(Mipomersen)
wmoefygvml(riyfirisgw) = mjsutbvxhg gvgsviukch (vinzikdbht, 19.85)
Phase 3
124
placebo
(Placebo)
cgfsbmbequ(dpnhkufzvl) = jcsjgizyco ayslevjrqg (dfouvjdkgw, 18.02)
-
21 Mar 2013
(Mipomersen)
cgfsbmbequ(dpnhkufzvl) = xkuxnigiwi ayslevjrqg (dfouvjdkgw, 26.99)
Phase 3
58
Placebo
(Placebo)
lbigucutwv(kfjqzbnhyn) = zbpadgyjgj ifybuqndkx (dsufrepyjs, 46.87)
-
21 Mar 2013
(Mipomersen)
lbigucutwv(kfjqzbnhyn) = dzvcrpacuc ifybuqndkx (dsufrepyjs, 24.71)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free